This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Human interleukin-2
DrugBank Accession Number
DB14865
Background

Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

Type
Biotech
Groups
Investigational
Synonyms
  • IL-2
  • INTERLEUKIN-2

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Human interleukin-2.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Human interleukin-2.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Human interleukin-2.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Human interleukin-2.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
FNO32LO217
CAS number
Not Available

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionDepression1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
4RecruitingTreatmentPulmonary Tuberculosis (TB)1
3CompletedTreatmentMetastatic Renal Cell Carcinoma ( mRCC)1
3CompletedTreatmentRenal Cell Carcinoma1
3Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID-19 Acute Respiratory Distress Syndrome / Cytokine Release Syndrome / Pulmonary Fibrosis1
3RecruitingTreatmentSystemic Lupus Erythematosus (SLE)2
3Unknown StatusPreventionHepatitis A / Human Immunodeficiency Virus (HIV) Infections / Viral Hepatitis B1
2Active Not RecruitingTreatmentChronic Graft Versus Host Disease1
2Active Not RecruitingTreatmentMalignant Solid Neoplasms / Metastatic Colorectal Adenocarcinoma / Metastatic Ovarian carcinoma / Metastatic Pancreatic (Ductal) Adenocarcinoma / Platinum-Resistant Ovarian Carcinoma / Recurrent High Grade Ovarian Serous Adenocarcinoma / Recurrent Ovarian Carcinosarcoma / Refractory Colorectal Carcinoma / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v81

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at May 20, 2019 14:31 / Updated at June 12, 2020 16:53